Earlier this month, NICE reiterated its position that Spravato should not be used for TRD, after an appeal of earlier rejections by J&J, with a final decision due in mid-December. In the ESCAPE ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

shares of J&J have lost 7.3% compared with the industry’s decline of 5.1%. Image Source: Zacks Investment Research More on the Latest Nod for JNJ's Spravato as Monotherapy The latest FDA nod for ...

J&J’s Janssen unit – which markets Spravato – said at the time it disagreed with the conclusions, which it claimed were “based on inaccurate assumptions…on the established positive ...

J&J Innovative Medicine's global therapeutic area head for neuroscience. Given its potential for abuse and misuse, Spravato will be only available through the FDA's Risk Evaluation and Mitigation ...

J&J's Spravato was FDA-approved in January as the only monotherapy for adults with treatment-resistant major depressive disorder. Feel unsure about the market’s next move? Copy trade alerts from ...

can one-day rival J&J’s (JNJ) FDA-approved depression therapy Spravato. Analyst Eddie Hickman’s bullish view comes at a time when the Canadian biopharma is advancing CYB003 in a multinational ...

Just building on everything that J&J has established with Spravato, but making it much more convenient for the patient, much more convenient for the provider. JN: Maybe just a a little more ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...